Vistagen Therapeutics (VTGN) Total Current Liabilities (2011 - 2026)

Vistagen Therapeutics has reported Total Current Liabilities for 14 years, with the latest figure at $12.8 million in Q1 2026.

• Quarterly Total Current Liabilities rose 1.45% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 1.45% YoY) and the FY2026 annual result came in at $12.8 million, up 1.45% from the prior year.
• Total Current Liabilities slipped to $12.8 million in Q1 2026 per VTGN's latest filing, from $13.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.6 million in Q3 2025 and troughed at $2.9 million in Q3 2023.
• A 5-year average of $7.8 million and a median of $6.2 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities slumped 54.64% in 2023, then soared 158.57% in 2024.
• Over 5 years, Total Current Liabilities stood at $4.3 million in 2022, then fell by 2.87% to $4.2 million in 2023, then jumped by 131.02% to $9.6 million in 2024, then soared by 40.62% to $13.5 million in 2025, then slipped by 5.43% to $12.8 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $12.8 million, $13.5 million, and $13.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.